Teva Pharmaceutical Industries Ltd. has launched the generic equivalent to Xeloda® (capecitabine) tablets, 150 mg and 500 mg, in the United States. Xeloda® is marketed by Genentech in the United States. Teva was the first to receive approval on its abbreviated new drug application from FDA on September 16, 2013 and is launching per a settlement agreement, according to the company.

Source: Teva Pharmaceutical Industries